D-0150-2017 Class II Terminated

Recalled by Pfizer Inc. — New York, NY

FDA drug recall D-0150-2017 was initiated by Pfizer Inc. on Nov 7, 2016 and is designated Class II. Reason for recall: Superpotent The recall status is terminated (terminated May 1, 2020). Affected quantity: 2,666 bottles.

Recall details

Product Type
Drugs
Report Date
Nov 30, 2016
Initiation Date
Nov 7, 2016
Termination Date
May 1, 2020
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
2,666 bottles

Product description

LEVOXYL(R) (levothyroxine sodium tablets, USP), 200 mcg, 100 count bottles, Rx only, Manufactured and Distributed by: King Pharmaceuticals, Inc., Bristol, TN 37620, NDC 60793-860-01

Reason for recall

Superpotent

Distribution pattern

Nationwide

Code information

16H21, Exp. 08/2017

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0150-2017
openFDA file date
Nov 19, 2026
Loaded by RegDataLab
Nov 20, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Need the full FDA record for Pfizer Inc.? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.

Get a free API key

How the connector works

Source: openFDA record for D-0150-2017. Report a data issue: hello@regdatalab.com.